Oxycontin Patents Not Infringed, Drug Cos. Say At Trial

Law360, New York (September 23, 2013, 7:08 PM EDT) -- Impax Laboratories Inc. and other drug makers said Monday that generic versions of Purdue Pharma LP’s OxyContin do not infringe Purdue-held patents, opening a patent trial that could help end Purdue’s monopoly on some formulations of the popular painkiller.

Impax, Teva Pharmaceuticals USA Inc. and Sandoz Inc. said that their versions of a tamper-resistant type of OxyContin, known generically as oxycodone, do not infringe patents that Purdue licensed from a university.

“The techniques we used are the conventional standard techniques always used in this industry,” attorney...
To view the full article, register now.